Eldelumab ELISA Kit

• Background:

  Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10) /Interferon-γ-inducible protein-10 (IP-10) . This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.

• Specifications:

  Eldelumab

• Product Name Alternative:

  BMS-936557, MDX-1100, CAS: 946414-98-8

• Detection Method:

  Colorimetric

• Assay Type:

  Quantitative

• Sample Type:

  Plasma, Serum

• Detection Range:

  0.31-5 μg/mL

• Recovery:

  80-120%

• Sensitivity:

  0.156 μg/ml

• Shipping Conditions:

  2-8 °C

• Storage Conditions:

  The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

• Notes:

  For Research Use Only.